Predict your next investment

Sage Science company logo
HEALTHCARE | Disease Diagnosis
sagescience.com

See what CB Insights has to offer

Stage

Loan | Alive

Total Raised

$18.12M

Last Raised

$680K | 1 yr ago

About Sage Science

Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.

Sage Science Headquarter Location

500 Cummings Center Suite 3150

Beverly, Massachusetts, 01915,

United States

978-922-1832

Latest Sage Science News

Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth

May 13, 2021

Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m. ET on Thursday, May 20 May 13, 2021 06:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718. Sage will provide details on its progress with SAGE-718, the company’s lead neuropsychiatry product candidate being explored for the potential treatment of cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. Sage will also share additional details on the recently announced data from the PARADIGM Study of SAGE-718 in patients with mild cognitive impairment due to Parkinson’s disease and the planned initiation of a Phase 2 placebo-controlled study in Huntington’s disease. Additionally, the Company will discuss the unmet need in Huntington’s disease, with participation and perspectives from a leading neurologist and a patient advocate. The Sage Science Spotlight is a new webcast series designed to take a deeper look at Sage’s work in brain health. It will complement Sage’s annual FutureCast event, which provides an update on the company’s overall research and development strategy and clinical progress in its key depression, neurology and neuropsychiatry franchise programs. Speakers on the May 20th webcast will include: Jim Doherty, Chief Research Officer, Sage Therapeutics Mike Quirk, Vice President, Pharmacology, Sage Therapeutics Aaron Koenig, Executive Medical Director, Early Development, Sage Therapeutics Dr. Samuel Frank, Associate Professor of Neurology, Beth Israel Deaconess Medical Center Seth Rotberg, Patient Advocate (Huntington’s Disease) The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com . A replay of the webcast will be available approximately two hours after the completion of the event. About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com . Forward-Looking Statements Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: statements regarding our planned research and development activities and the opportunity to help patients in various indications. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may encounter hurdles and delays in initiation, conduct or completion of our planned clinical trials, including as a result of slower than expected site initiation or enrollment; decisions or actions of the FDA may affect the initiation and timing of clinical trials and our ability to proceed with further development; ongoing and future non-clinical and clinical results may not meet their primary or key secondary endpoints or support further development; we may encounter adverse events at any stage of development that negatively impact further development or that require additional nonclinical and clinical work which may not yield positive results; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates which may delay our timing or change our plans, or otherwise negatively impact our business; as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sage Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sage Science is included in 4 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

975 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

9,302 items

Companies that use or incorporate digital technology into their health/wellness product & service offerings. Only those that have raised funding after 01/01/2010

Sage Science Patents

Sage Science has filed 20 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/15/2018

8/11/2020

Molecular biology, DNA, DNA sequencing, Molecular biology techniques, Biotechnology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/15/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/11/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA, DNA sequencing, Molecular biology techniques, Biotechnology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sage Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sage Science Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.